Jessi Corcoran Acquires 5,000 Shares of Medline (NASDAQ:MDLN) Stock

Posted by Brenda Bartman on Jun 11th, 2026

Medline (NASDAQ:MDLN – Get Free Report) insider Jessi Corcoran purchased 5,000 shares of the stock in a transaction on Friday, June 5th. The stock was acquired at an average cost of $34.15 per share, for a total transaction of $170,750.00. Following the acquisition, the insider owned 5,000 shares in the company, valued at approximately $170,750. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through this link.

Medline Stock Up 1.5%

NASDAQ:MDLN opened at $36.54 on Thursday. The firm has a 50-day simple moving average of $41.06. Medline has a twelve month low of $32.81 and a twelve month high of $50.88. The stock has a market cap of $48.00 billion and a PE ratio of 114.19. The company has a current ratio of 4.41, a quick ratio of 2.51 and a debt-to-equity ratio of 0.65.

Medline (NASDAQ:MDLN – Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.33 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.04. The firm had revenue of $7.35 billion for the quarter. The business’s revenue was up 10.7% compared to the same quarter last year. On average, equities research analysts expect that Medline will post 1.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Robert W. Baird dropped their target price on Medline from $57.00 to $45.00 and set an “outperform” rating for the company in a research report on Wednesday, June 3rd. BNP Paribas Exane dropped their target price on Medline from $49.00 to $40.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th. Morgan Stanley boosted their target price on Medline from $48.00 to $52.00 and gave the stock an “overweight” rating in a research report on Monday, March 2nd. BTIG Research restated a “buy” rating and issued a $55.00 target price on shares of Medline in a research report on Thursday, May 7th. Finally, William Blair restated an “outperform” rating on shares of Medline in a research report on Thursday, June 4th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $50.54.

Check Out Our Latest Analysis on Medline

Hedge Funds Weigh In On Medline

A number of large investors have recently bought and sold shares of the stock. Carlyle Group Inc. purchased a new position in Medline in the 4th quarter worth approximately $9,042,728,000. H&F Corporate Investors X Ltd. purchased a new position in Medline in the 4th quarter worth approximately $4,179,591,000. Vanguard Group Inc. purchased a new position in Medline in the 4th quarter worth approximately $793,278,000. Morgan Stanley purchased a new position in Medline in the 4th quarter worth approximately $636,807,000. Finally, Capital Research Global Investors bought a new stake in shares of Medline in the 4th quarter worth approximately $620,937,000.

Medline News Summary

Here are the key news stories impacting Medline this week:

Positive Sentiment: Recent insider buying is helping sentiment, with Principal Accounting Officer Jessi L. Corcoran purchasing 5,000 shares at $34.15, signaling confidence from management.
Positive Sentiment: Investors appear to be digesting Medline’s recently completed debt refinancing and new term loan structure as a cleaner balance sheet setup that reduces near-term financing uncertainty.
Positive Sentiment: The large secondary offering was sold by existing shareholders rather than Medline issuing new shares, which may ease concerns about direct company-level dilution.
Neutral Sentiment: Medline’s presentation at the Goldman Sachs healthcare conference kept the stock in focus, but the provided details did not include a major new operating catalyst.
Neutral Sentiment: Management’s recent investor and analyst attention may be reinforcing the view that the company remains fundamentally solid after its strong recent earnings report.
Negative Sentiment: Fresh securities-fraud investigation headlines could pressure the shares by raising legal and disclosure-risk concerns, even though no wrongdoing has been established.
Negative Sentiment: Some analyst commentary has turned more cautious, including a recent Barclays target cut to $45 from $50, citing margin pressure concerns.

Medline Company Profile

(Get Free Report)

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.